Recombinant Human ARHGDIB Protein, N-His

Introduction

Recombinant Human ARHGDIB Protein, also known as Rho GDP-dissociation inhibitor 2 (RhoGDI2), is a protein that plays a critical role in regulating the activity of Rho GTPases. Rho GTPases are a family of signaling proteins that control various cellular processes, such as cell migration, proliferation, and differentiation. Dysregulation of Rho GTPase activity has been linked to various diseases, making ARHGDIB an important target for research and potential therapeutic applications.

Structure of Recombinant Human ARHGDIB Protein

The ARHGDIB gene encodes for a protein consisting of 204 amino acids with a molecular weight of approximately 23 kDa. The recombinant protein is produced in a laboratory setting using genetic engineering techniques, resulting in a highly pure and homogeneous protein. The protein is composed of two domains: an N-terminal RhoGDI domain and a C-terminal RhoGDI-binding domain. These domains are responsible for the protein’s ability to interact with and regulate the activity of Rho GTPases.

Activity of Recombinant Human ARHGDIB Protein

The primary function of ARHGDIB is to inhibit the activity of Rho GTPases by binding to and sequestering them in the cytoplasm. This prevents the GTPases from interacting with their downstream effectors and carrying out their signaling functions. ARHGDIB has been shown to specifically interact with RhoA, RhoB, and RhoC, as well as other members of the Rho family, such as Rac1 and Cdc42.

In addition to its inhibitory role, ARHGDIB has also been found to have a regulatory effect on Rho GTPase activation. Studies have shown that ARHGDIB can modulate the GTPase activity of RhoA by promoting its activation or inactivation, depending on the cellular context. This highlights the complex and dynamic nature of ARHGDIB’s role in regulating Rho GTPase signaling.

Applications of Recombinant Human ARHGDIB Protein

The ability of ARHGDIB to regulate Rho GTPase activity makes it a valuable tool in various research fields, including cancer, cardiovascular disease, and neurological disorders. For example, ARHGDIB has been found to be downregulated in certain types of cancer, leading to increased Rho GTPase activity and promoting tumor growth and metastasis. By studying the effects of ARHGDIB on Rho GTPase activity, researchers can gain a better understanding of the mechanisms underlying cancer progression and potentially identify new therapeutic targets.

In addition to its role in disease research, ARHGDIB has also been investigated for its potential therapeutic applications. Studies have shown that recombinant ARHGDIB protein can inhibit Rho GTPase activity and suppress tumor growth in animal models, making it a promising candidate for cancer treatment. Furthermore, ARHGDIB has been found to have a protective effect on the cardiovascular system by inhibiting Rho GTPase-mediated inflammation and promoting vascular stability.

Conclusion

In summary, Recombinant Human ARHGDIB Protein is a highly pure and homogeneous protein that plays a critical role in regulating the activity of Rho GTPases. Its ability to inhibit and regulate Rho GTPase activity makes it a valuable tool in various research fields and a potential therapeutic target for diseases associated with dysregulated Rho GTPase signaling. Further studies on the structure, activity, and applications of ARHGDIB will continue to advance our understanding of its role in cellular processes and its potential as a therapeutic agent.

ProteoGenix catalogue number ARO-P11315. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 17.92 kDa; Fragment: Asn66-Glu201; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet